cetuximab

You may need to have blood tests for several weeks after your cetuximab treatment has ended.

There may be other drugs that can interact with cetuximab.

Your doctor or pharmacist can provide more information about cetuximab.

Based on information from related drugs, cetuximab may pass into breast milk.

Monoclonal antibodies such as cetuximab may not work for some people.

The survival benefit of adding cetuximab to standard chemotherapy was almost three months.

After your cetuximab infusion, your doctor will need to watch you for about an hour.

Cetuximab binds to such receptors and turns off that signal.

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.

There is no specific information comparing use of cetuximab in children with its use in other age groups.

You should not breast-feed a baby while you are receiving cetuximab and for at least 60 days after your treatment ends.

Symptoms of a cetuximab overdose are not known.

The results of ongoing studies to clarify the role of cetuximab in this disease are awaited with interest.

Severe (sometimes fatal) infusion reactions have occurred with cetuximab.

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein).

If you are also being treated with radiation, you will receive cetuximab one week before your radiation treatment.

Call your doctor for instructions if you miss an appointment for your cetuximab infusion.

Because of potential harm to the infant, breast-feeding is not recommended while using cetuximab and for 2 months after the end of treatment.

However, the monoclonal antibody cetuximab has been used in compassionate use for treatment of Ménétrier's disease.

If you have any of these other conditions, you may need a dose adjustment or special tests to safely use cetuximab:

A 2010 review concluded that the combination of cetuximab and platin/5-fluorouracil should be considered the current standard first-line regimen.

Immunohistochemistry is used to determine patients who may benefit from therapeutic antibodies such as Erbitux (cetuximab).

Cetuximab (marketed as Erbitux) targets the epidermal growth factor receptor.

One of the more serious side effects of cetuximab therapy is the incidence of acne-like rash.

This study found no improvement in survival or disease-free survival with the addition of cetuximab to the conventional chemotherapy.